ANDA 213542, held by Caplin. Gatifloxacin.
As of Nov 16, 2026, ANDA 213542 (Gatifloxacin), held by Caplin, was first approved by FDA on Nov 3, 2021, with 0 approved supplements and 0 published complete response letters.
Gatifloxacin ophthalmic solution 0.5 % is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis* Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 3, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gatifloxacin0.5% · solution/drops;ophthalmic | Gatifloxacin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters